EU/3/13/1179

About

On 5 August 2013, orphan designation (EU/3/13/1179) was granted by the European Commission to Larode Ltd, United Kingdom, for recombinant human growth hormone modified by fusion with two hydrophilic polypeptide chains for the treatment of growth-hormone deficiency.

This medicine is now known as somavaratan.

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in December 2018 on request of the Sponsor.

 

Key facts

Active substance
Recombinant human growth hormone modified by fusion with two hydrophilic polypeptide chains (somavaratan)
Disease / condition
Treatment of growth-hormone deficiency
Date of first decision
05/08/2013
Outcome
Withdrawn
EU designation number
EU/3/13/1179

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Larode Ltd
Rhode Farm
Priory Lane
Selborne
Hampshire GU34 3BU
United Kingdom
Tel. +44 (0)1420 511 012
E-mail: info@larode.org

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating